Breaking News

Financial Report: Alkermes

May 23, 2013

Revenues up 25% in the quarter

Alkermes

4Q Revenues: $163.4 million (+25%)

4Q Earnings: $3.0 million (loss of $63.4 million 4Q12)

FY Revenues: $575.5 million (+48%)

FY Earnings: $25.0 million (loss of $113.7 million FY12)

Comments: Revenues from the company’s five key commercial products for the quarter grew 26% to $89.5 million. Results reflect the completion of the merger of Alkermes with Elan Drug Technologies (EDT) in Sept. 2011. For the year, revenues included $50.0 million of intellectual property license revenue unrelated to key development programs.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.